Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

The Effect of Duloxetine Treatment on Cognition in Patients With Fibromyalgia

Bibliographic Data

ID19303883
AuthorsRichard Mohs, Richard C Mohs (0000-0002-3765-6287, Eli Lilly (United States)), Philip Mease, Lesley M Arnold (0000-0003-0393-9948), Fujun Wang (0000-0002-4283-4631), Jonna Ahl (0000-0002-5661-6053), Paula J Gaynor, Madelaine M Wohlreich (corresponding author)
Year2012
Volume74
Issue6
Pages628-634
Publication date2012-07-01
Open AccessNo
TypeARTICLE
VenuePsychosomatic Medicine (JOURNAL)
Journal identifiersISSN: 0033-3174 • E-ISSN: 1534-7796
PublisherOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/psy.0b013e31825b9855
PMID22753629
OpenAlexW1998210533
LanguageEN
Citations received1
References cited30

OBJECTIVES: To determine the effect of duloxetine treatment on cognition in patients with fibromyalgia. METHODS: Cognitive testing was conducted in a subset of adult patients in a randomized, double-blind, placebo-controlled trial of duloxetine. Patients met the American College of Rheumatology criteria for fibromyalgia and had a score of 4 or higher on the Brief Pain Inventory 24-hour average pain severity item. Patients who consented to cognitive testing were randomized to duloxetine (n = 80) or placebo (n = 76). The primary end point was at Week 12. Speed of processing on tasks requiring visual attention, working memory, and executive function was assessed with a Symbol Digit Substitution Test and Trail-Making Test A and B. Episodic memory was tested using the Verbal Learning and Recall Test. The change from baseline to end point (last-observation-carried-forward analysis) was analyzed by an analysis of covariance model, which included baseline, treatment, investigator, and treatment-by-investigator interaction. RESULTS: Most of the patients were white (89%) women (92%), ranging in age from 21 to 88 years. Mean scores on the cognitive tests were within 2 SD of published scores for similar-aged participants in the general population, indicating no substantial impairment. Baseline-to-end point changes in cognitive scores did not differ significantly between duloxetine and placebo treatment groups. CONCLUSIONS: Although scores differed somewhat from norms for age, substantial cognitive impairment was not evident in patients with fibromyalgia as assessed by the Symbol Digit Substitution Test, Trail-Making Test, and Verbal Learning and Recall Test. Overall, duloxetine treatment had neither positive nor negative effects on cognition. TRIAL REGISTRATION: Clintrials.gov NCT00673452

Cognition · Cognitive test · Digit symbol substitution test · Duloxetine · Fibromyalgia · Memory span · Neuropsychology · Physical therapy · Placebo · Psychiatry · Randomized controlled trial · Recall · Trail Making Test · Verbal learning · Working memory · Clinical Psychology · Fibromyalgia and Chronic Fatigue Syndrome Research · Internal Medicine · Medicine · Osteoarthritis Treatment and Mechanisms · Psychology · Psychosomatic Disorders and Their Treatments

  • Memory complaints and cognitive performance in fibromyalgia and chronic pain

    Open Access•Antoni Castel, Rosalía Cascón-Pereira et al.•Scandinavian Journal of Psychology•2021

  • The american college of rheumatology 1990 criteria for the classification of fibromyalgia

    Open Access•Frederick Wolfe, Hugh A Smythe et al.•Arthritis & Rheumatism•1990

  • Trail Making Test A and B

    Tom N Tombaugh, T Tombaugh•Archives of Clinical Neuropsycholog…•2004

Citations per year0.2
Citation span2021 - 2021 (1)
Highly citedNo

Tools

Open DOISci-Hub
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae